GSK
$47.03Change from previous close: −0.32%Absolute change: −$0.15
At a glance
- Revenue growth
- +4.11%
- 2025 vs 2024
- Net income growth
- +121.98%
- 2025 vs 2024
- Net margin
- 17.5%
- 2024: 8.2%
Financial data
Amounts in millions of GBP; per-share values in GBP; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 32,667 | 31,376 | 30,328 | 29,324 | — |
| Cost of revenue | 9,017 | 9,048 | 8,565 | 9,554 | — |
| Gross profit | 23,650 | 22,328 | 21,763 | 19,770 | — |
| Selling, general and administrative | 9,088 | 11,015 | 9,385 | 8,372 | — |
| Research and development | 7,525 | 6,401 | 6,223 | 5,488 | — |
| Operating income | 8,338 | 5,542 | 7,345 | 6,729 | — |
| EBIT | 8,088 | 4,117 | 6,789 | 6,454 | — |
| EBITDA | 10,402 | 6,668 | 9,083 | 8,601 | — |
| Interest expense | 687 | 640 | 725 | 826 | — |
| Pre-tax income | 7,401 | 3,477 | 6,064 | 5,628 | — |
| Income tax | 1,112 | 526 | 756 | 707 | — |
| Net income | 5,716 | 2,575 | 4,928 | 14,956 | — |
| Net income to common shareholders | 5,716 | 2,575 | 4,928 | 14,956 | — |
| Basic EPS | 2.82 | 1.26 | 2.43 | 7.43 | — |
| Diluted EPS | 2.78 | 1.24 | 2.40 | 7.32 | — |
| Average shares (basic) | 2,026 | 2,039 | 2,026 | 2,013 | — |
| Average shares (diluted) | 2,059 | 2,071 | 2,056 | 2,042 | — |